Last updated: March 8, 2026
Welcome to Pharma Surge. By using our application, you agree to these Terms of Service ("Terms"). Please read them carefully.
By accessing or using the Pharma Surge app ("App"), you agree to be bound by these Terms. If you do not agree, please do not use the App.
Pharma Surge is a pharmaceutical industry news aggregation platform. We provide curated news, pipeline tracking, and industry analysis from publicly available sources. The App offers both free and premium (Pro) subscription tiers.
Free Tier: Free users may read up to 20 articles per day across all sections.
Pro Subscription: Pro subscribers enjoy unlimited article access and additional premium features.
The App aggregates and links to news content from third-party pharmaceutical industry sources. We may also present native summaries, structured tags, related developments, and pipeline or regulatory reference information derived from publicly available sources. We do not claim ownership of third-party content. All original content, design, and features of the App are the intellectual property of Pharma Surge.
You agree not to:
The App is provided "as is" without warranties of any kind. We do not guarantee the accuracy, completeness, or timeliness of any content. The information in the App is for general informational purposes only and should not be construed as medical, legal, or investment advice.
To the maximum extent permitted by law, Pharma Surge shall not be liable for any indirect, incidental, special, or consequential damages arising from your use of the App.
We reserve the right to suspend or terminate your account at any time for violations of these Terms. You may delete your account at any time in the App (Settings → Delete Account) or by contacting us. Deleting your Pharma Surge account does not automatically cancel an active App Store or Google Play subscription; subscription cancellation must be managed through the applicable store account settings.
We may modify these Terms at any time. Continued use of the App after changes constitutes acceptance of the new Terms. We will notify users of significant changes.
These Terms shall be governed by and construed in accordance with the laws of the People's Republic of China, without regard to conflict of law principles.
If you have questions about these Terms, please contact us at:
qixiaobing2025@gmail.com